Vancouver, British Columbia, Canada — BiOasis Technologies has announced the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest(TM) blood test for Alzheimer’s disease.

Working in collaboration with Fleet Bioprocessing and OxFabs in the United Kingdom, BiOasis reports generating numerous antibodies and assessing their performance in prototype assays. The best performing mAbs were selected for use within production prototypes. The completion of this project enables the company to initiate the validation of Cognitest with the use of clinical samples.

During the coming months BiOasis says it plans to secure a number of blood samples from several sources for the purpose of assessing the technical performance of Cognitest.

"The selection of monoclonal antibodies is an important step in the Cognitest program," says Rob Hutchison, BiOasis chairman and CEO.
"Our strategy is to create new intellectual property and ensure ownership of key components within our products. We are now working to
assess Cognitest using human samples from North America and Europe. Our intention is to expand the validation studies by collaborating with clinical thought leaders interested in an easy-to-use quantitative test for Alzheimer’s disease. The ability to diagnose Alzheimer’s has always been known to be very difficult due to the fact that many forms of dementia mimic Alzheimer’s and as such a simple quick blood test would provide physicians with a tool to combat this dreadful disease."

Cognitest is a proprietary diagnostic test for the diagnosis of Alzheimer’s disease that biOasis is developing. Current initiatives within the
Cognitest program include product and method development, validation using human samples, and regulatory approval in Europe. To enable
faster adoption and greater use of Cognitest the company intends to out-license it to leading in vitro diagnostic companies.

BiOasis Technologies Inc